Portfolio Company News
Press Releases
October 15, 2018
James Nolan discussed global clinical trial crisis in London
July 12, 2018
Anthony Esposito, Jr. Joins InClinica as Senior Director of Quality Assurance
InClinica, a global clinical CRO, announced today that Anthony J. Esposito, Jr. has been appointed Senior Director of Quality Assurance.
July 11, 2018
Jeffrey Schwartz Joins InClinica as Assistant Vice President of Business Development, Americas
InClinica, a global clinical CRO, announced today that Jeffrey Schwartz has been appointed Assistant Vice President of Business Development, representing the company’s operations throughout North and South America.
June 13, 2018
James Nolan discussed global clinical trial strategy in Edinburgh.
May 9, 2018
Todd Koch Joins InClinica as Global Trial Manager
InClinica, a global clinical CRO, announced today that Todd Koch has been appointed Global Trial Manager. In his new role, Koch will be responsible for the day-to-day leadership and management of clinical trials.
April 18, 2018
Karthik Kumar Joins InClinica as Business Development Manager
In his new role, Kumar will be responsible for supporting clinical research organization sales and business development activities, generating leads, and providing customer relationship management and clinical operations management support.
April 5, 2018
Julio Casoy Joins InClinica as Chief Medical Officer
Dr. Casoy has more than 20 years of experience in the pharmaceutical industry, specializing in rheumatology with a long history of work in women’s health. Before joining InClinica, he served as Senior Vice President of Medical Affairs at Turing Pharmaceuticals where he was responsible for establishing and managing medical affairs including data generation, data dissemination, compliance, and KOL management. Prior to that, he oversaw the medical affairs of various pharmaceutical companies, most notably, spending more than a decade leading Wyeth’s international medical affairs in Brazil.
April 3, 2018
Donald L. Very, Jr. Joins InClinica as Chief Technical Analyst, Devices and Diagnostics
Dr. Very has more than 25 years of industry experience in device development, diagnostic and pharmaceutical assay development, and performance qualification in such diverse clinical areas as oncology, infectious disease, and metabolic disease. He is well-versed in each clinical trial step: research, development, performance validation, clinical trial design and implementation, and regulatory approval.
February 5, 2018
InClinica CEO Speaks at the National Conference for Clinical Research in Israel
James Nolan discussed the global clinical trial crisis in Tel Aviv
December 15, 2017
Shirley L. Steiner Joins InClinica as Senior Global Clinical Operations Director
November 29, 2017
InClinica CEO Speaks at the 2nd World Congress on Clinical Trials in Diabetes in Berlin
James Nolan provided industry professionals guidance on selecting a CRO and an IP attorney
October 31, 2017
InClinica Strengthens European Team
Nathan McCavery Joins InClinica as Director of Business Development
October 25, 2017
InClinica CEO Speaks at The Symposium on Clinical Pain Trials in Europe
James Nolan to provide industry perspective on issues facing clinical trials
September 21, 2017
Roland Mahr Joins InClinica as Vice President and General Manager of Asia-Pacific
September 8, 2017
InClinica CEO to Speak at the 3rd International Congress on Clinical Trials for Medical Devices
James Nolan to address designing a clinical program for success
June 20, 2017
InClinica Expands American Operations
Global Clinical CRO hires two executives, promotes new Vice President.
June 6, 2017
InClinica CEO to Speak at Biocom’s First “Concept to Commercialization” Presentation
James Nolan kicks off series with lecture on current state of CRO model.
February 17, 2017
InClinica Expands European Presence
Maxime Stevens Appointed as Senior Vice President of Development.
December 7, 2016
InClinica Chief Medical Officer Educates Boston University Students on Drug Development
Edward Brennan to present lecture on the drug development process at Boston University School of Medicine.
November 29, 2016
InClinica CEO Speaks to World Congress on Clinical Trials in Diabetes
James Nolan to present lectures on the current state of diabetes trials.
October 14, 2016
InClinica Strengthens Presence in Asia-Pacific Region
Company opens new office to serve as its Asia-Pacific headquarters.
August 18, 2016
InClinica Expands European Presence
InClinica, a global, clinical CRO, announced that Dr. Thomas Morris, has been appointed Medical Director of InClinica Ltd., representing the company’s European operations.
August 3, 2016
Philadelphia CRO Acquired by Investment Fund; Relaunched InClinica Poised for Global Growth
Velocity Fund Partners, a Pittsburgh private equity company, has announced the acquisition of the Philadelphia clinical contract research organization (CRO) Indipharm and is relaunching the CRO as InClinica.
March 22, 2016
Clinical Research Malaysia Bestows its Industry Recognition Award to Jeffrey Scott Yablon
Jeffrey Scott Yablon has received an Industry Recognition Award from Clinical Research Malaysia for his outstanding efforts in promoting Malaysia as a preferred destination for Industry Sponsored Research (ISR).
Media Coverage
August 2018
Wall Street Bets On Biotech IPOs Amid ‘Science Fiction’ Frenzy
The first seven months of 2018 saw 38 biotech companies file initial public offerings — bullishly outpacing last year amid improved sentiment for the sector.
Investor’s Business Daily
March 2018
House Fails to Pass ‘Right-to-Try’ Bill
House Democrats and two Republicans came together to defeat the Right-to-Try bill, dealing a blow to a bill supported by President Donald Trump, Vice President Mike Pence and House Speaker Paul Ryan.
PharmaVoice
May 2017
In just a few short years, hepatitis infections could go from a serious disease to one that will be rare. Pharmaceutical companies have done much to address hepatitis in recent years. Today, hepatitis B is preventable with vaccination, and recent advances in treatment have made hepatitis C curable.
PharmaVoice
April 2,2017
Future of drug development likely Asia-centric, says InClinica’s Yablon
This week we get thoughts and ideas from global clinical contract research organisation, InClinica’s executive vice-president and general manager (Asia-Pacific), Jeffrey Scott Yablon.
The Sun Daily
March 2017
VIDEO: The State of Clinical Research in Malaysia
Jeffrey Scott Yablon, Executive Vice President and General Manager of InClinica, Asia/Pacific is interviewed by Bernama Today focusing on clinical research and its potential for growth in Malaysia.
Bernama Today
March 2017
InClinica finds clinical research opportunities in Malaysia, as well as the region.
Business Times
February 16, 2017
Taking the road to medical innovation
Clinical research is defined as the medical field involving the discovery of new drugs, medical devices or medical protocol. If you think clinical research is something done by people in lab coats in hospitals, you’re not wrong.
Focusweek
January 23, 2017
When it comes to diabetes, will marketers break with tradition?
The fiercely competitive diabetes drug market is in line for a dramatic overhaul, one that would place more emphasis than ever on the well-being of the consumer.
MM&M
December 24, 2016
Malaysia: A Base for Clinical Development?
InClinica executive vice president and general manager (Asia-Pacific) Jeffrey Scott Yablon says Malaysia can be the leader in ASEAN clinical development over the next ten years if the industry continues to grow, evolve and get support from the government.
Public Private Cover Story | Malaysia SME P&P 04 December 24, 2016 – January 6, 2017
December 23, 2016
As CROs Eye Asia, Inclinica Chooses Malaysia
Jeffrey S. Yablon is the Executive Vice President and General Manager for Asia Pacific of InClinica, a US-based clinical Contract Research Organisation (CRO). He joins us on the Breakfast Grille to discuss the CRO business model and why the company has chosen Malaysia as its regional hub.
BFM 89.9
November 30, 2016
WCTD 2016 (World Congress on Clinical Trials in Diabetes)
Mr. James Nolan, CEO of the contract research organization InClinica (Wayne, PA), highlighted seven key challenges for enrollment in modern clinical trials from an industry perspective.
Close Concerns
November 30, 2016
InClinica CEO Speaks To World Congress On Clinical Trials In Diabetes
James Nolan, CEO of InClinica, Inc. ‒ a global, clinical CRO ‒ will present two lectures to the World Congress on Clinical Trials in Diabetes on Wednesday, November 30 in Berlin.
BioSpace
November 15, 2016
Diabesity Highlighted
Diabetes expert and researcher Professor Paul Zimmet AO delivered a talk on Diabetes In The Asia Pacific Region: Current and Future Trends, at the International Medical University. The talk highlighted the prevalence of Diabesity (obesity and type 2 diabetes) in Asia particularly in China, India, Singapore and Malaysia where economic progression and prosperity coupled with an overindulgence in rich, fatty foods and a sedentary lifestyle has resulted in an alarming increase in type 2 diabetes among the young.
The New Straits Times
November 7, 2016
InClinica expands global operations with exec hires in the U.S. and Europe
Velocity Fund Partners clearly has big plans for its newly acquired and relaunched CRO InClinica. Since the acquisition was announced in August, InClinica has been in a restless hiring mood, appointing three regional VPs of business development in the U.S. and Europe.
FierceBioTech
October 18, 2016
US-based, PE-backed InClinica sets up Asia Pacific headquarter in KL
US-based clinical contract research organization (CRO) InClinica has opened a new regional head-office in Kuala Lumpur in a bid to expand its global network of clinical research in Asia Pacific.
Deal Street Asia
October 18, 2016
InClinica Expands European Presence
InClinica, a global, clinical CRO, announced that Dr. Thomas Morris, has been appointed Medical Director of InClinica Ltd., representing the company’s European operations.
BioSpace
August 4, 2016
Velocity Fund launches InClinica from acquired CRO IndiPharm
Pittsburgh’s Velocity Fund Partners has picked up CRO IndiPharm for an undisclosed amount, renaming the Philadelphia firm InClinica.
FierceBioTech
August 3, 2016
Former Highmark CEO’s private equity fund makes acquisition
The private equity fund launched earlier in 2016 by former Highmark Inc. CEO Kenneth Melani has acquired a company.
Pittsburgh Business Times
August 3, 2016
Valley Forge CRO gets new owner, new name
Velocity Fund Partners, a Pittsburgh private equity company, has acquired Valley Forge, Pennsylvania-based clinical contract research organization Indipharm and is relaunching the CRO as InClinica.
Philadelphia Business Journal